Psilocybin and MDMA -- Therapeutic Use Permitted in Australia from July 1st 2023

Home | Psychedelics Law Blog | Psilocybin and MDMA — Therapeutic Use Permitted in Australia from July 1st 2023 Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so doing, Australia will position itself as among the first countries to provide a legal pathway to psychedelic therapies. Therapeutic Goods Administration Medicines and other therapeutic products are regulated nationally in Australia by the Therapeutic Goods Administration (TGA). Using a scheduling system, the TGA classifies medicines and chemicals and controls how they are made available to the public. Substances are classified into Schedules according to the level of regulatory control over their availability that is considered necessary to protect public health and safety. The Schedules are published in the Poisons Standard and are given legal effect through state and territory legislation. The Poisons Standard is a record of decisions made by the TGA on the classification of medicines and chemicals into the Schedules. Schedule 8 concerns controlled drugs, being medicines thought to require strict legislative controls, such as opioid analgesics. Schedule 9 is for prohibited substances, which are those considered to have no therapeutic use while also being open to abuse, such as heroin. Presently, psilocybin and MDMA are both Schedule 9 prohibited substances. The use of Schedule 9 substances is limited to authorized research and analytical purposes. Amendment to the Poisons Standard On February 3rd 2023, the TGA published an amendment to the Poisons Standard that will take effect on July 1st 2023. From that date, psilocybin may be used for treatment-resistant depression (TRD) and MDMA may be used for post-traumatic stress disorder (PTSD). For those purposes, respectively, the substances will be controlled drugs classified in Schedule 8. For all other purposes, they will remain prohibited in Schedule 9. From July 1st 2023, each substance may be prescribed or supplied, for the permitted purpose, only by a medical practitioner with an authority governing that substance. They may also be used in approved clinical trials. Only psychiatrists with the necessary authority are considered by the TGA to have the training and expertise to diagnose and appropriately treat the relevant conditions. In Australia, a consultation with a psychiatrist generally requires a referral from a general medical practitioner. The reclassification of certain uses of psilocybin and MDMA occurred because the TGA concluded that the benefits to patients and public health now outweigh the risks, even though there are yet no established treatment protocols. The TGA regards the reclassifications as aligned with the current body of clinical evidence, which is limited to TRD for psilocybin and PTSD for MDMA. The body of evidence demonstrating efficacy of these substances for the treatment of other conditions is considered insufficient to justify increased access for therapeutic use. In its decision, the TGA noted that therapeutic uses of psilocybin and MDMA are largely prohibited outside clinical trials in many countries, including Canada, New Zealand, the U.K., and the E.U. Nonetheless, the TGA conceded that therapeutic uses of these substances are under review in many countries, including the US, where the FDA has designated MDMA as a "breakthrough" therapy for TRD. Check Out Our Psychedelics Law Services Share Twitter Facebook LinkedIn E-mail Comment Mathew Alderson Mathew is an international transactional lawyer and corporate advisor with a focus on entertainment, technology and creative industries. Described as a “game-changing attorney” by Variety Magazine, Mathew leads our China office and media and entertainment practice from Shanghai. He represents major Hollywood studios and producers on both motion picture and television projects. Mathew’s clientele extends to tech companies, promoters and event management companies, architectural firms, universities and publishers. Harris Sliwoski Attorney Read more posts [email protected] Read More International, Psilocybin Related Posts April 21, 2026 Trump's Executive Order on Psychedelics March 19, 2026 Operating a Psychedelic or Cannabis Retreat Abroad? Legal Liability Risks for U.S. Operators May 20, 2025 DEA Gives Church Green Light on Ayahuasca April 2, 2025 Conducting Psychedelic Retreats Abroad: Protecting Yourself and Participants March 17, 2025 "Sincere Religious Belief" is an Evolving Standard for Psychedelic Churches February 17, 2025 Psychedelics and Trademark: INTA 2025 Annual Meeting in San Diego! February 14, 2025 Ninth Circuit Issues Disappointing Ruling on Terminally Ill Patients and Psilocybin December 30, 2024 Oregon Psilocybin: State of the State (2024) August 20, 2024 Updates on MDMA, Ketamine, and the Future of Psychedelic Therapies July 4, 2024 Happy 4th of July! June 18, 2024 Oregon Psilocybin: Preparing for the End of Local Ownership Rules May 29, 2024 FDA Grants Priority Status to New MDMA Drug April 23, 2024 Psychedelics and the Military: An Unlikely Alliance April 19, 2024 Arizona's Psilocybin Legislation February 27, 2024 Oregon Ketamine Clinics: New Potential Restrictions on Corporate Practice of Medicine Leave a comment Cancel reply